Search

Your search keyword '"Zucchelli, Gemma"' showing total 30 results
Start Over Author "Zucchelli, Gemma"
30 results on '"Zucchelli, Gemma"'

2. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

Author

Moretto, Roberto, Rossini, Daniele, Conca, Veronica, Lonardi, Sara, Rasola, Cosimo, Antoniotti, Carlotta, Santini, Daniele, Marmorino, Federica, Tomasello, Gianluca, Borelli, Beatrice, Caponnetto, Salvatore, Zucchelli, Gemma, Zaniboni, Alberto, Ambrosini, Margherita, Buonadonna, Angela, Fanchini, Laura, Cupini, Samanta, Masi, Gianluca, Falcone, Alfredo, and Cremolini, Chiara

Published
2021
Full Text
View/download PDF

3. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable

Author

Ongaro, Elena, Cremolini, Chiara, Rossini, Daniele, Corti, Francesca, Pagani, Filippo, Morelli, Luca, Urbani, Lucio, Masi, Gianluca, Sposito, Carlo, Filippi, Beatrice, Borelli, Beatrice, Zucchelli, Gemma, Moretto, Roberto, Boccaccino, Alessandra, Solaini, Leonardo, de Braud, Filippo, Mazzaferro, Vincenzo, Falcone, Alfredo, Cucchetti, Alessandro, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

4. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

Author

Borelli, Beatrice, Moretto, Roberto, Lonardi, Sara, Bonetti, Andrea, Antoniotti, Carlotta, Pietrantonio, Filippo, Masi, Gianluca, Burgio, Valentina, Marmorino, Federica, Salvatore, Lisa, Rossini, Daniele, Zaniboni, Alberto, Zucchelli, Gemma, Martignetti, Angelo, Di Battista, Monica, Pella, Nicoletta, Passardi, Alessandro, Boccaccino, Alessandra, Leone, Francesco, Colombo, Camilla, Granetto, Cristina, Vannini, Francesca, Marsico, Valentina Angela, Martinelli, Erika, Antonuzzo, Lorenzo, Vitello, Stefano, Delliponti, Laura, Boni, Luca, Cremolini, Chiara, and Falcone, Alfredo

Published
2018
Full Text
View/download PDF

5. Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib

Author

Schirripa, Marta, Borelli, Beatrice, D’Aurizio, Romina, Lubrano, Simone, Cremolini, Chiara, Zucchelli, Gemma, Antoniotti, Carlotta, Marmorino, Federica, Prete, Alessandra Anna, Murgioni, Sabina, Bergamo, Francesca, Zagonel, Vittorina, Tuccoli, Andrea, Marranci, Andrea, Rizzo, Milena, Tedeschi, Lorena, Magnoni, Letizia, Falcone, Alfredo, Loupakis, Fotios, and Poliseno, Laura

Published
2019
Full Text
View/download PDF

6. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest

Author

Cremolini, Chiara, Casagrande, Mariaelena, Loupakis, Fotios, Aprile, Giuseppe, Bergamo, Francesca, Masi, Gianluca, Moretto R, Roberto, Pietrantonio, Filippo, Marmorino, Federica, Zucchelli, Gemma, Tomasello, Gianluca, Tonini, Giuseppe, Allegrini, Giacomo, Granetto, Cristina, Ferrari, Laura, Urbani, Lucio, Cillo, Umberto, Pilati, Pierluigi, Sensi, Elisa, Pellegrinelli, Alessio, Milione, Massimo, Fontanini, Gabriella, and Falcone, Alfredo

Published
2017
Full Text
View/download PDF

7. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials

Author

Cremolini, Chiara, Milione, Massimo, Marmorino, Federica, Morano, Federica, Zucchelli, Gemma, Mennitto, Alessia, Prisciandaro, Michele, Lonardi, Sara, Pellegrinelli, Alessio, Rossini, Daniele, Bergamo, Francesca, Aprile, Giuseppe, Urbani, Lucio, Morelli, Luca, Schirripa, Marta, Cardellino, Giovanni Gerardo, Fassan, Matteo, Fontanini, Gabriella, de Braud, Filippo, Mazzaferro, Vincenzo, Falcone, Alfredo, and Pietrantonio, Filippo

Published
2018
Full Text
View/download PDF

8. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

Author

Randon, Giovanni, Fucà, Giovanni, Rossini, Daniele, Raimondi, Alessandra, Pagani, Filippo, Perrone, Federica, Tamborini, Elena, Busico, Adele, Peverelli, Giorgia, Morano, Federica, Niger, Monica, Antista, Maria, Corallo, Salvatore, Saggio, Serena, Borelli, Beatrice, Zucchelli, Gemma, Milione, Massimo, Pruneri, Giancarlo, Di Bartolomeo, Maria, Falcone, Alfredo, de Braud, Filippo, Cremolini, Chiara, and Pietrantonio, Filippo

Published
2019
Full Text
View/download PDF

9. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer

Author

Antoniotti, Carlotta, primary, Marmorino, Federica, additional, Boccaccino, Alessandra, additional, Martini, Silvia, additional, Antista, Maria, additional, Rossini, Daniele, additional, Zuco, Valentina, additional, Prisciandaro, Michele, additional, Conca, Veronica, additional, Zucchelli, Gemma, additional, Borelli, Beatrice, additional, Cosentino, Paola, additional, Germani, Marco M., additional, Bosco, Maria F., additional, Carullo, Martina, additional, Vetere, Guglielmo, additional, Moretto, Roberto, additional, Giordano, Mirella, additional, Masi, Gianluca, additional, Pietrantonio, Filippo, additional, Zaffaroni, Nadia, additional, and Cremolini, Chiara, additional

Published
2022
Full Text
View/download PDF

10. Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study.

Author

Marmorino, Federica, primary, Antoniotti, Carlotta, additional, Boccaccino, Alessandra, additional, Antista, Maria, additional, Zaffaroni, Nadia, additional, Zucchelli, Gemma, additional, Martinetti, Antonia, additional, Campi, Elisa, additional, Rossini, Daniele, additional, Sottotetti, Elisa, additional, Borelli, Beatrice, additional, Corti, Francesca, additional, Conca, Veronica, additional, Moretto, Roberto, additional, Germani, Marco Maria, additional, Falcone, Alfredo, additional, Giordano, Mirella, additional, Masi, Gianluca, additional, Pietrantonio, Filippo, additional, and Cremolini, Chiara, additional

Published
2021
Full Text
View/download PDF

11. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest

Author

Moretto, Roberto, primary, Rossini, Daniele, additional, Zucchelli, Gemma, additional, Lonardi, Sara, additional, Bergamo, Francesca, additional, Santini, Daniele, additional, Cupini, Samanta, additional, Tomasello, Gianluca, additional, Caponnetto, Salvatore, additional, Zaniboni, Alberto, additional, Antoniotti, Carlotta, additional, Pietrantonio, Filippo, additional, Buonadonna, Angela, additional, Marmorino, Federica, additional, Bordonaro, Roberto, additional, Fea, Elena, additional, Tamburini, Emiliano, additional, Boccaccino, Alessandra, additional, Grande, Roberta, additional, Aprile, Giuseppe, additional, Falcone, Alfredo, additional, and Cremolini, Chiara, additional

Published
2020
Full Text
View/download PDF

12. Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study.

Author

Antoniotti, Carlotta, primary, Marmorino, Federica, additional, Lonardi, Sara, additional, Corti, Francesca, additional, Rossini, Daniele, additional, Moretto, Roberto, additional, Ugolini, Clara, additional, Giordano, Mirella, additional, Tamburini, Emiliano, additional, Santini, Daniele, additional, Aprile, Giuseppe, additional, Bordonaro, Roberto, additional, Zucchelli, Gemma, additional, Fontanini, Gabriella, additional, Lenz, Heinz-Josef, additional, Falcone, Alfredo, additional, Korn, Wolfgang Michael, additional, and Cremolini, Chiara, additional

Published
2020
Full Text
View/download PDF

13. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation

Author

Giannini, Riccardo, primary, Zucchelli, Gemma, additional, Giordano, Mirella, additional, Ugolini, Clara, additional, Moretto, Roberto, additional, Ambryszewska, Katarzyna, additional, Leonardi, Michele, additional, Sensi, Elisa, additional, Morano, Federica, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Falcone, Alfredo, additional, and Fontanini, Gabriella, additional

Published
2020
Full Text
View/download PDF

14. Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification—A pooled analysis of TRIBE and TRIBE2 studies by GONO.

Author

Zucchelli, Gemma, primary, Moretto, Roberto, additional, Rossini, Daniele, additional, Lonardi, Sara, additional, Murgioni, Sabina, additional, Tonini, Giuseppe, additional, Cupini, Samanta, additional, Ratti, Margherita, additional, Urbano, Federica, additional, Libertini, Michela, additional, Antoniotti, Carlotta, additional, Corallo, Salvatore, additional, Buonadonna, Angela, additional, Bordonaro, Roberto, additional, Ricci, Vincenzo, additional, Tamburini, Emiliano, additional, Grande, Roberta, additional, Aprile, Giuseppe, additional, Falcone, Alfredo, additional, and Cremolini, Chiara, additional

Published
2020
Full Text
View/download PDF

16. Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Author

Moretto, Roberto, primary, Morano, Federica, additional, Ongaro, Elena, additional, Rossini, Daniele, additional, Pietrantonio, Filippo, additional, Casagrande, Mariaelena, additional, Antoniotti, Carlotta, additional, Corallo, Salvatore, additional, Marmorino, Federica, additional, Cortiula, Francesco, additional, Nichetti, Federico, additional, Borelli, Beatrice, additional, Zucchelli, Gemma, additional, Boccaccino, Alessandra, additional, Masi, Gianluca, additional, de Braud, Filippo, additional, Falcone, Alfredo, additional, and Cremolini, Chiara, additional

Published
2019
Full Text
View/download PDF

17. Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Author

Zucchelli, Gemma, primary, Moretto, Roberto, additional, Schirripa, Marta, additional, Intini, Rossana, additional, Rossini, Daniele, additional, Santini, Daniele, additional, Pizzo, Claudio, additional, Antoniotti, Carlotta, additional, Borelli, Beatrice, additional, Marmorino, Federica, additional, Urbano, Federica, additional, Burgio, Valentina, additional, Libertini, Michela, additional, Prisciandaro, Michele, additional, Buonadonna, Angela, additional, Bustreo, Sara, additional, Allegrini, Giacomo, additional, Ricci, Vincenzo, additional, Cremolini, Chiara, additional, and Falcone, Alfredo, additional

Published
2019
Full Text
View/download PDF

18. Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.

Author

Rossini, Daniele, primary, Pagani, Filippo, additional, Pellino, Antonio, additional, Dell'Aquila, Emanuela, additional, Liscia, Nicole, additional, Bensi, Maria, additional, Germani, Marco Maria, additional, Masi, Gianluca, additional, Moretto, Roberto, additional, Santini, Daniele, additional, Salvatore, Lisa, additional, Scartozzi, Mario, additional, Lonardi, Sara, additional, Zucchelli, Gemma, additional, Ongaro, Elena, additional, Falcone, Alfredo, additional, Pietrantonio, Filippo, additional, and Cremolini, Chiara, additional

Published
2019
Full Text
View/download PDF

19. Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Author

Marmorino, Federica, primary, Rossini, Daniele, additional, Aprile, Giuseppe, additional, Casagrande, Mariaelena, additional, Lonardi, Sara, additional, Murgioni, Sabina, additional, Dell'Aquila, Emanuela, additional, Tomasello, Gianluca, additional, Antoniotti, Carlotta, additional, Borelli, Beatrice, additional, Zucchelli, Gemma, additional, Urbano, Federica, additional, Ronzoni, Monica, additional, Zaniboni, Alberto, additional, Manglaviti, Sara, additional, Buonadonna, Angela, additional, Ritorto, Giuliana, additional, Allegrini, Giacomo, additional, Falcone, Alfredo, additional, and Cremolini, Chiara, additional

Published
2019
Full Text
View/download PDF

20. The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.

Author

Moretto, Roberto, primary, Giannini, Riccardo, additional, Zucchelli, Gemma, additional, Giordano, Mirella, additional, Pietrantonio, Filippo, additional, Antoniotti, Carlotta, additional, Ugolini, Clara, additional, Morano, Federica, additional, Marmorino, Federica, additional, Sensi, Elisa, additional, Belfiore, Antonino, additional, Rossini, Daniele, additional, Lupi, Cristiana, additional, Masi, Gianluca, additional, Borelli, Beatrice, additional, Ongaro, Elena, additional, Boccaccino, Alessandra, additional, Falcone, Alfredo, additional, Fontanini, Gabriella, additional, and Cremolini, Chiara, additional

Published
2018
Full Text
View/download PDF

21. Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC).

Author

Ongaro, Elena, primary, Rossini, Daniele, additional, Pietrantonio, Filippo, additional, Morano, Federica, additional, De Braud, Filippo G., additional, Mazzaferro, Vincenzo, additional, Corti, Francesca, additional, Randon, Giovanni, additional, Raimondi, Alessandra, additional, Battaglia, Luigi, additional, Morelli, Luca, additional, Urbani, Lucio, additional, Masi, Gianluca, additional, Moretto, Roberto, additional, Antoniotti, Carlotta, additional, Marmorino, Federica, additional, Borelli, Beatrice, additional, Zucchelli, Gemma, additional, Cremolini, Chiara, additional, and Falcone, Alfredo, additional

Published
2018
Full Text
View/download PDF

22. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Author

Cremolini, Chiara, primary, Rossini, Daniele, additional, Martinelli, Erika, additional, Pietrantonio, Filippo, additional, Lonardi, Sara, additional, Noventa, Silvia, additional, Tamburini, Emiliano, additional, Frassineti, Giovanni Luca, additional, Mosconi, Stefania, additional, Nichetti, Federico, additional, Murgioni, Sabina, additional, Troiani, Teresa, additional, Borelli, Beatrice, additional, Zucchelli, Gemma, additional, Dal Maso, Alessandro, additional, Sforza, Vincenzo, additional, Masi, Gianluca, additional, Antoniotti, Carlotta, additional, Di Bartolomeo, Maria, additional, Miceli, Rosalba, additional, Ciardiello, Fortunato, additional, and Falcone, Alfredo, additional

Published
2018
Full Text
View/download PDF

23. Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).

Author

Antoniotti, Carlotta, primary, Marmorino, Federica, additional, Pennati, Marzia, additional, Zaffaroni, Nadia, additional, Rossini, Daniele, additional, Borelli, Beatrice, additional, Zucchelli, Gemma, additional, Moretto, Roberto, additional, Pietrantonio, Filippo, additional, Masi, Gianluca, additional, Vannini, Francesca, additional, Colombo, Camilla, additional, Gini, Serenella, additional, Saettini, Alessandra, additional, Delliponti, Laura, additional, Brunetti, Isa Maura, additional, Pfanner, Elisabetta, additional, Falcone, Alfredo, additional, and Cremolini, Chiara, additional

Published
2018
Full Text
View/download PDF

24. Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.

Author

Marmorino, Federica, primary, Cremolini, Chiara, additional, Pietrantonio, Filippo, additional, Pellegrinelli, Alessio, additional, Zucchelli, Gemma, additional, Loupakis, Fotios, additional, Lonardi, Sara, additional, Aprile, Giuseppe, additional, Morano, Federica, additional, Prisciandaro, Michele, additional, Masi, Gianluca, additional, Mennitto, Alessia, additional, Bergamo, Francesca, additional, Cardellino, Giovanni Gerardo, additional, Fassan, Matteo, additional, Casagrande, Mariaelena, additional, Milione, Massimo, additional, Fontanini, Gabriella, additional, de Braud, Filippo, additional, and Falcone, Alfredo, additional

Published
2018
Full Text
View/download PDF

25. A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice

Author

Borelli, Beatrice, primary, Zucchelli, Gemma, additional, Rossini, Daniele, additional, Cremolini, Chiara, additional, Antoniotti, Carlotta, additional, Moretto, Roberto, additional, Marmorino, Federica, additional, Colombo, Camilla, additional, Vannini, Francesca, additional, Delliponti, Laura, additional, Spione, Mario, additional, Ongaro, Elena, additional, Masi, Gianluca, additional, Brunetti, Isa Maura, additional, Pfanner, Elisabetta, additional, Salvatore, Lisa, additional, and Falcone, Alfredo, additional

Published
2018
Full Text
View/download PDF

26. Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study

Author

Moretto, Roberto, primary, Cremolini, Chiara, additional, Morano, Federica, additional, Berenato, Rosa, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Rossini, Daniele, additional, Antoniotti, Carlotta, additional, Marmorino, Federica, additional, Gloghini, Annunziata, additional, Busico, Adele, additional, Zucchelli, Gemma, additional, Baratelli, Chiara, additional, Tamburini, Emiliano, additional, Capone, Iolanda, additional, Volpi, Chiara, additional, Milione, Massimo, additional, Di Maio, Massimo, additional, Fontanini, Gabriella, additional, de Braud, Filippo, additional, Falcone, Alfredo, additional, and Pietrantonio, Filippo, additional

Published
2017
Full Text
View/download PDF

27. Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.

Author

Cremolini, Chiara, primary, Morano, Federica, additional, Moretto, Roberto, additional, Berenato, Rosa, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Rossini, Daniele, additional, Gloghini, Annunziata, additional, Busico, Adele, additional, Zucchelli, Gemma, additional, Baratelli, Chiara, additional, Tamburini, Emiliano, additional, Capone, Iolanda, additional, Volpi, Chiara, additional, Milione, Massimo, additional, Di Maio, Massimo, additional, Fontanini, Gabriella, additional, De Braud, Filippo G., additional, Falcone, Alfredo, additional, and Pietrantonio, Filippo, additional

Published
2017
Full Text
View/download PDF

28. P-271 - Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study

Author

Moretto, Roberto, Cremolini, Chiara, Morano, Federica, Berenato, Rosa, Tamborini, Elena, Perrone, Federica, Rossini, Daniele, Antoniotti, Carlotta, Marmorino, Federica, Gloghini, Annunziata, Busico, Adele, Zucchelli, Gemma, Baratelli, Chiara, Tamburini, Emiliano, Capone, Iolanda, Volpi, Chiara, Milione, Massimo, Di Maio, Massimo, Fontanini, Gabriella, de Braud, Filippo, Falcone, Alfredo, and Pietrantonio, Filippo

Published
2017
Full Text
View/download PDF

29. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Author

Daniele Rossini, Teresa Troiani, Emiliano Tamburini, Giovanni Luca Frassineti, Carlotta Antoniotti, Sabina Murgioni, S. Noventa, Stefania Mosconi, Erika Martinelli, Fortunato Ciardiello, Alfredo Falcone, Gianluca Masi, Rosalba Miceli, Sara Lonardi, Gemma Zucchelli, Filippo Pietrantonio, Maria Di Bartolomeo, Chiara Cremolini, Federico Nichetti, Alessandro Dal Maso, Beatrice Borelli, Vincenzo Sforza, Cremolini, Chiara, Rossini, Daniele, Martinelli, Erika, Pietrantonio, Filippo, Lonardi, Sara, Noventa, Silvia, Tamburini, Emiliano, Frassineti, Giovanni Luca, Mosconi, Stefania, Nichetti, Federico, Murgioni, Sabina, Troiani, Teresa, Borelli, Beatrice, Zucchelli, Gemma, Dal Maso, Alessandro, Sforza, Vincenzo, Masi, Gianluca, Antoniotti, Carlotta, Di Bartolomeo, Maria, Miceli, Rosalba, Ciardiello, Fortunato, and Falcone, Alfredo

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Pyrrolidines, Colorectal cancer, Disease, Trifluridine, chemistry.chemical_compound, 0302 clinical medicine, Gastrointestinal Cancer, 80 and over, Refractory colorectal cancer, Regorafenib, TAS-102, Trifluridine/tipiracil, Adult, Aged, Aged, 80 and over, Colorectal Neoplasms, Drug Combinations, Female, Humans, Italy, Middle Aged, Progression-Free Survival, Registries, Thymine, Uracil, Short life, 030220 oncology & carcinogenesis, medicine.medical_specialty, 03 medical and health sciences, Refractory, Internal medicine, medicine, business.industry, Compassionate Use, Nomogram, medicine.disease, digestive system diseases, TAS‐102, 030104 developmental biology, chemistry, Life expectancy, business
Abstract

Background TAS-102 is indicated for patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, available therapies. Given the complete inefficacy in half of patients, the lack of predictive factors, the palliative setting, and the financial and clinical toxicity, optimizing the cost-benefit ratio is crucial. The “ColonLife” nomogram allows an estimate of the 12-week life expectancy of patients with refractory mCRC. Materials and Methods We collected data from patients treated at eight Italian centers in the compassionate use program. Baseline characteristics of patients who were or were not progression free at 6 months were compared. The discriminative ability of the ColonLife nomogram was assessed. Among patients who received both TAS-102 and regorafenib, clinical outcomes of the two sequences were compared. Results This study included 341 patients. Six (2%) and 93 (27%) patients achieved response and disease stabilization, respectively. The median progression-free survival (PFS) was 2.4 months with an estimated 6-month PFS rate of 19%; the median overall survival (OS) was 6.2 months. An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, normal lactate dehydrogenase (LDH), and a time from the diagnosis of metastatic disease of >18 months were independently associated with higher chances of a patient being progression free at 6 months. The discriminative ability of ColonLife was confirmed. Among 121 patients who received both regorafenib and TAS-102, no differences in first or second PFS or OS were reported between the two sequences. Conclusion One out of five patients achieves clinical benefit with TAS-102. ECOG PS, LDH, and time from diagnosis of metastatic disease may help to identify these patients. Excluding patients with very short life expectancy appears a reasonable approach. Implications for Practice Improving the cost-efficacy ratio of TAS-102 in metastatic colorectal cancer is needed to spare useless toxicities in a definitely palliative setting. Eastern Cooperative Oncology Group performance status, lactate dehydrogenase levels, and time from the diagnosis of metastatic disease may help to identify patients more likely to achieve benefit. Properly designed prognostic tools (i.e., the “ColonLife” nomogram) may enable excluding from further treatments patients with very limited life expectancy.

Published
2018

30. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable

Author

Alessandra Boccaccino, Daniele Rossini, Filippo Pagani, Vincenzo Mazzaferro, Gianluca Masi, Elena Ongaro, Alfredo Falcone, Chiara Cremolini, Lucio Urbani, Beatrice Borelli, Luca Morelli, Roberto Moretto, Francesca Corti, Carlo Sposito, Alessandro Cucchetti, Leonardo Solaini, Beatrice Filippi, Filippo de Braud, Gemma Zucchelli, Filippo Pietrantonio, Ongaro, Elena, Cremolini, Chiara, Rossini, Daniele, Corti, Francesca, Pagani, Filippo, Morelli, Luca, Urbani, Lucio, Masi, Gianluca, Sposito, Carlo, Filippi, Beatrice, Borelli, Beatrice, Zucchelli, Gemma, Moretto, Roberto, Boccaccino, Alessandra, Solaini, Leonardo, de Braud, Filippo, Mazzaferro, Vincenzo, Falcone, Alfredo, Cucchetti, Alessandro, and Pietrantonio, Filippo

Subjects
Cancer Research, medicine.medical_specialty, extrahepatic disease progression, liver-limited disease, metastatic colorectal cancer, Colorectal cancer, business.industry, Disease progression, Disease, Liver resections, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, Gastroenterology, Oncology, Internal medicine, Cohort, medicine, In patient, Multivariable model, business, Cohort study, Original Research
Abstract

Background: No tools to predict the probability of extrahepatic disease progression (ePD) of initially unresectable, liver-limited metastatic colorectal cancer (mCRC) are currently available. To estimate the likelihood to develop ePD and to identify clinical and molecular factors that could predict extrahepatic progression-free survival (ePFS), we conducted an observational, retrospective, multicentre cohort study. Methods: We retrospectively identified a cohort of 225 patients with initially unresectable liver-limited disease (LLD), treated from January 2004 to December 2017 with first-line doublets or triplet plus a biological agent at two Italian institutions. Results: 173 (77%) patients experienced ePD which occurred within 1, 2 or 3 years from the diagnosis of mCRC in 15%, 49% and 66% of patients, respectively. Globally, 164 (73%) patients underwent a liver resection at some point of their disease history, and 54 (33%) of them underwent a subsequent locoregional treatment. Age > 70 years, locoregional nodal involvement at diagnosis of colorectal cancer and ≥4 liver metastases were significantly associated with higher risk of ePD while liver resections were associated with reduced risk of ePD. In the multivariable model, number of liver metastases (subdistribution HR, SHR 1.63, 95% CI 1.12 to 2.36; p = 0.01) and liver resections (SHR 0.43, 95% CI 0.29 to 0.63; p = 0.001) were still associated with ePD. Number of liver metastases < 4, no nodal involvement at diagnosis and liver resections were also associated with prolonged ePFS. Conclusions: The identified clinical factors could help physicians in personalising the intensity and aggressiveness of liver-directed treatments in patients with mCRC with initially unresectable LLD.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results